Capecitabine Market

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blood cell counts. It is not recommended in people with kidney problems. Use during pregnancy may result in harm to the baby. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-fluorouracil and tegafur.

Capecitabine Market contains market size and forecasts of Capecitabine in global, including the following market information:

Global Capecitabine Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Capecitabine Market Sales, 2017-2022, 2023-2028, (Kg)

Global top five Capecitabine companies in 2021 (%)

The global Capecitabine market was valued at 1055.9 million in 2021 and is projected to reach US$ 1027.9 million by 2028, at a CAGR of -0.4% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

500 mg Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Capecitabine include Roche, Teva, Mylan, Hikma, Hengrui Medicine, Cipla, Reliance Group and Hetero, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Capecitabine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Capecitabine Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Kg)

Global Capecitabine Market Segment Percentages, by Type, 2021 (%)

500 mg

150 mg

Global Capecitabine Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Kg)

Global Capecitabine Market Segment Percentages, by Application, 2021 (%)

Breast Cancer

Colorectal Cancer

Stomach Cancer

Global Capecitabine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Kg)

Global Capecitabine Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Capecitabine revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Capecitabine revenues share in global market, 2021 (%)

Key companies Capecitabine sales in global market, 2017-2022 (Estimated), (Kg)

Key companies Capecitabine sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Roche

Teva

Mylan

Hikma

Hengrui Medicine

Cipla

Reliance Group

Hetero